tbuckley/cabot-search huggingface dataset:
Disrupted tenogenesis in masseter as a potential cause of micrognathia
Authors: Chao Liu, Nan Zhou, Nan Li, Tian Xu, Xiaoyan Chen, Hailing Zhou, Ailun Xie, Han Liu, Lei Zhu, Songlin Wang, Jing Xiao
Journal: International Journal of Oral Science (2022)

Abstract Micrognathia is a severe craniofacial deformity affecting appearance and survival. Previous studies revealed that multiple factors involved in the osteogenesis of mandibular bone have contributed to micrognathia, but concerned little on factors other than osteogenesis. In the current study, we found that ectopic activation of Fgf8 by Osr2-cre in the presumptive mesenchyme for masseter tendon in mice led to micrognathia, masseter regression, and the disrupted patterning and differentiation of masseter tendon. Since Myf5-cre;Rosa26R-Fgf8 mice exhibited the normal masseter and mandibular bone, the possibility that the micrognathia and masseter regression resulted directly from the over-expressed Fgf8 was excluded. Further investigation disclosed that a series of chondrogenic markers were ectopically activated in the developing Osr2-cre;Rosa26R-Fgf8 masseter tendon, while the mechanical sensing in the masseter and mandibular bone was obviously reduced. Thus, it suggested that the micrognathia in Osr2-cre;Rosa26R-Fgf8 mice resulted secondarily from the reduced mechanical force transmitted to mandibular bone. Consistently, when tenogenic or myogenic components were deleted from the developing mandibles, both the micrognathia and masseter degeneration took place with the decreased mechanical sensing in mandibular bone, which verified that the loss of mechanical force transmitted by masseter tendon could result in micrognathia. Furthermore, it appeared that the micrognathia resulting from the disrupted tenogenesis was attributed to the impaired osteogenic specification, instead of the differentiation in the periosteal progenitors. Our findings disclose a novel mechanism for mandibular morphogenesis, and shed light on the prevention and treatment for micrognathia.
Correction to: Unraveling the Genetic Basis for the Rapid Diversification of Male Genitalia between <i>Drosophila</i> Species
Journal: Molecular Biology and Evolution (2022)

The authors have since discovered an error in one of the RNAi lines used, which meant that they actually targeted the gene Sulf1 on chromosome arm 3R instead of Surf1 on chromosome arm 3L as reported.The paper has been corrected to remove these data for Sulf1 from the text of the paper, Figure 2 and supplementary files 5 and 6.The authors have also further clarified the genes that were first tested in Tanaka et al., (2015) and those data reanalysed here in the context of new mapping and gene expression data.
Response to “A commentary on “Prevalence and outcomes of transurethral resection versus radical cystectomy for muscle-infiltrating bladder cancer in the United States: A population-based cohort study” [Int. J. Surg. (2022) 103 106693]” (Int J Surg 2022;104:106802)
Authors: Yuzhong Ye, Yongqiang Zheng, Kai Yu, Xiaoping Zhang
Journal: International Journal of Surgery (2022)
Design and Properties of Antimicrobial Biomaterials Surfaces
Authors: Babak Mehrjou, Yuzheng Wu, Pei Liu, Guomin Wang, Paul K. Chu
Journal: Advanced Healthcare Materials (2022)

Emergence of antibiotic-resistance pathogens has caused serious health issues and if the current trend is to continue, treatment of the infection will become complicated and even unsuccessful due to new antimicrobial resistance (AMR). Therefore, there is a global drive to identify new methods to treat infection and develop better antibacterial materials and therapy. Although new and more potent antibiotics have aided the fight against microbes, they only offer a temporary solution because future bacteria strains may become resistant to these antibiotics and drugs. Recently, application of non-biological methods such as, electrical currents and photothermal/dynamic therapies to kill bacteria, reveal new approaches to design antimicrobial biomaterials, as complications stemming from drug-resistant bacteria can be obviated. Furthermore, recent research has focused on mimicking the surface patterns on plants and insects such as lotus leaves and dragonfly wings. Bio-inspired micro/nano patterns have been replicated on a variety of biomaterials to improve the bacterial resistance and other properties with good success. This is an exciting research area with immense practical and clinical potentials. In this review, recent advances in the application of chemical/biological approaches to combat bacterial infection and AMR are summarized and the related mechanisms are discussed.
Infection, pathology and interferon treatment of the SARS-CoV-2 Omicron BA.1 variant in juvenile, adult and aged Syrian hamsters
Authors: Lunzhi Yuan, Huachen Zhu, Peiwen Chen, Ming Zhou, Jian Ma, Xuan Liu, Kun Wu, Rirong Chen, Qiwei Liu, Huan Yu, Lifeng Li, Jia Wang, Yali Zhang, Shengxiang Ge, Quan Yuan, Qiyi Tang, Tong Cheng, Yi Guan, Ningshao Xia
Journal: Cellular and Molecular Immunology (2022)

Abstract The new predominant circulating SARS-CoV-2 variant, Omicron, can robustly escape current vaccines and neutralizing antibodies. Although Omicron has been reported to have milder replication and disease manifestations than some earlier variants, its pathogenicity in different age groups has not been well elucidated. Here, we report that the SARS-CoV-2 Omicron BA.1 sublineage causes elevated infection and lung pathogenesis in juvenile and aged hamsters, with more body weight loss, respiratory tract viral burden, and lung injury in these hamsters than in adult hamsters. Juvenile hamsters show a reduced interferon response against Omicron BA.1 infection, whereas aged hamsters show excessive proinflammatory cytokine expression, delayed viral clearance, and aggravated lung injury. Early inhaled IFN-α2b treatment suppresses Omicron BA.1 infection and lung pathogenesis in juvenile and adult hamsters. Overall, the data suggest that the diverse patterns of the innate immune response affect the disease outcomes of Omicron BA.1 infection in different age groups.
The puzzle of ideography
Authors: Olivier Morin
Journal: Behavioral and Brain Sciences (2022)

Abstract An ideography is a general-purpose code made of pictures that do not encode language, which can be used autonomously – not just as a mnemonic prop – to encode information on a broad range of topics. Why are viable ideographies so hard to find? I contend that self-sufficient graphic codes need to be narrowly specialized. Writing systems are only an apparent exception: At their core, they are notations of a spoken language. Even if they also encode nonlinguistic information, they are useless to someone who lacks linguistic competence in the encoded language or a related one. The versatility of writing is thus vicarious: Writing borrows it from spoken language. Why is it so difficult to build a fully generalist graphic code? The most widespread answer points to a learnability problem. We possess specialized cognitive resources for learning spoken language, but lack them for graphic codes. I argue in favor of a different account: What is difficult about graphic codes is not so much learning or teaching them as getting every user to learn and teach the same code. This standardization problem does not affect spoken or signed languages as much. Those are based on cheap and transient signals, allowing for easy online repairing of miscommunication, and require face-to-face interactions where the advantages of common ground are maximized. Graphic codes lack these advantages, which makes them smaller in size and more specialized.
Ownership psychology as a cognitive adaptation: A minimalist model
Authors: Pascal Boyer
Journal: Behavioral and Brain Sciences (2022)

Ownership is universal and ubiquitous in human societies, yet the psychology underpinning ownership intuitions is generally not described in a coherent and computationally tractable manner. Ownership intuitions are commonly assumed to derive from culturally transmitted social norms, or from a mentally represented implicit theory. While the social norms account is entirely ad hoc, the mental theory requires prior assumptions about possession and ownership that must be explained. Here I propose such an explanation, arguing that the intuitions result from the interaction of two cognitive systems. One of these handles competitive interactions for the possession of resources observed in many species including humans. The other handles mutually beneficial cooperation between agents, as observed in communal sharing, collective action and trade. Together, these systems attend to specific cues in the environment, and produce definite intuitions such as "this is hers," "that is not mine." This computational model provides an explanation for ownership intuitions, not just in straightforward cases of property, but also in disputed ownership (squatters, indigenous rights), historical changes (abolition of slavery), as well as apparently marginal cases, such as the questions, whether people own their seats on the bus, or their places in a queue, and how people understand "cultural appropriation" and slavery. In contrast to some previous theories, the model is empirically testable and free of ad hoc stipulations.
Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Authors: J. Haanen, M. Obeid, L. Spain, F. Carbonnel, Y. Wang, C. Robert, A.R. Lyon, W. Wick, M. Kostine, S. Peters, K. Jordan, J. Larkin
Journal: Annals of Oncology (2022)
Negative trials over and over again: How can we do better?
Authors: J Ricardo McFaline-Figueroa, Patrick Y Wen
Journal: Neuro-Oncology (2022)

Journal Article Negative trials over and over again: How can we do better? Get access J Ricardo McFaline-Figueroa, J Ricardo McFaline-Figueroa Center For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, USADivision of Neuro-Oncology, Department of Neurology, Brigham and Women’s Hospital, Boston, USAHarvard Medical School, Boston, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Patrick Y Wen Patrick Y Wen Center For Neuro-Oncology, Dana-Farber Cancer Institute, Boston, USADivision of Neuro-Oncology, Department of Neurology, Brigham and Women’s Hospital, Boston, USAHarvard Medical School, Boston, USA Corresponding Author: Patrick Y. Wen, MD, Center For Neuro-Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA 02420, USA (patrick_wen@dfci.harvard.edu). Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, Volume 25, Issue 1, January 2023, Pages 1–3, https://doi.org/10.1093/neuonc/noac226 Published: 18 October 2022 Article history Published: 18 October 2022 Corrected and typeset: 28 October 2022
IARC Perspective on Oral Cancer Prevention
Authors: Véronique Bouvard, Suzanne T. Nethan, Deependra Singh, Saman Warnakulasuriya, Ravi Mehrotra, Anil K. Chaturvedi, Tony Hsiu-Hsi Chen, Olalekan A. Ayo-Yusuf, Prakash C. Gupta, Alexander R. Kerr, Wanninayake M. Tilakaratne, Devasena Anantharaman, David I. Conway, Ann Gillenwater, Newell W. Johnson, Luiz P. Kowalski, Maria E. Leon, Olena Mandrik, Toru Nagao, Vinayak M. Prasad, Kunnambath Ramadas, Felipe Roitberg, Pierre Saintigny, Rengaswamy Sankaranarayanan, Alan R. Santos-Silva, Dhirendra N. Sinha, Patravoot Vatanasapt, Rosnah B. Zain, Béatrice Lauby-Secretan
Journal: New England Journal of Medicine (2022)

In a review of strategies for preventing oral cancer, an expert panel reports that the use of tobacco (both smoking and smokeless), areca nut exposure, and heavy alcohol consumption are major contributors to this illness.
Foreword
Authors: Jignesh Dalal, MD
Journal: Leukemia (2022)

Leukemia is a hematological malignancy caused by clonal proliferation of abnormal lymphoid or hematopoietic cells in the bone marrow and/or lymphoid system. There are many different types of leukemias. Acute leukemia progresses fast, and patients' condition deteriorates quickly without treatment; while chronic leukemia progresses slowly, and the patients may stay with the disease for a long time even without treatment. Acute leukemia is predominantly the malignancy of lymphoid or hematopoietic precursors (blasts). Based on cell origin, acute leukemia can be classified as acute lymphoblastic leukemia, acute myeloid leukemia, or acute leukemia of ambiguous lineage. Chronic leukemia represents the malignancy of mature or maturing lymphoid or hematopoietic cells, and predominantly affects adults. Leukemias can be further classified into many subtypes with the incorporation of more clinical, phenotypic, and genetic information. The frontline treatment for leukemia is chemotherapy. Tremendous advances have been made in the leukemia field during the last several decades. Our understanding of the biology of different types of leukemia has been significantly improved through a huge amount of basic and clinical research. The application of advanced diagnostic technologies has led to the identification of many new leukemia subtypes with distinct genetic defects. Some of these defects have the potential for targeted therapy. CONTINUE READING…..
List of Contributors
Authors: List of Contributors
Journal: Leukemia (2022)

AGNIESZKA JANUS, MD, PHDDepartment of General Hematology, Copernicus Memorial Hospital, Lodz, Poland ALESSANDRO FIORENTINI, MDHematology department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Via Conca 71, 60126 Ancona, Italy ATTILIO OLIVIERI, MDHematology department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Via Conca 71, 60126 Ancona, Italy DEBORA CAPELLI, MDHematology department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Via Conca 71, 60126 Ancona, Italy DEYANIRA ESCALANTE-BAUTISTA, MSLaboratorio de Hematobiología, ENMyH, Instituto Politécnico Nacional, Mexico City, Mexico; Unidad de Investigación Médica en Genética Humana, UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social IMSS, Av. Cuauhtémoc 330, Col Doctores, Delegación Cuauhtémoc, 06720, Mexico City, Mexico DIEGO MENOTTI, MDHematology department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Via Conca 71, 60126 Ancona, Italy DORIS CERECEDO, PHDLaboratorio de Hematobiología, Escuela Nacional de Medicina y Homeopatía, I.P.N., Guillermo Massieu Helguera No. 239, Col. La Escalera Ticomán, 07320, Ciudad de México (CDMX), Mexico FRANCESCO SARACENI, MDHematology department, University of Ancona, Azienda Ospedaliera Universitaria Ospedali Riuniti di Ancona, Via Conca 71, 60126 Ancona, Italy HAYDEÉ ROSAS-VARGAS, PHDUnidad de Investigación Médica en Genética Humana, UMAE Hospital de Pediatría, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social IMSS, Av. Cuauhtémoc 330, Col Doctores, Delegación Cuauhtémoc, 06720, Mexico City, Mexico LEI ZHANG, PHDDepartment of Pathology and Laboratory Medicine, Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine, Kansas City, USA MOTOHARU SHIBUSAWA, MDIMS group Shinmatsudo Central General Hospital, Department of Hematology, Chiba, Japan PRABHJOT KAUR, MDDepartment of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, USA SAHIBU SULTAN M. HABEEBU, MD, PHDDepartment of Pathology and Laboratory Medicine, Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine, Kansas City, USA SEVGI GÖZDAŞOĞLU, MDDepartment of Pediatrics, Divisions of Hematology and Oncology, Ankara University Medical School, Ankara, Turkey TADEUSZ ROBAK, MD, PHDDepartment of Hematology, Medical University of Lodz, Lodz, Poland TETSUYA TANIMOTO, MDNavitas Clinic Kawasaki, Kanagawa, Japan WAHAB A. KHAN, PHDDepartment of Pathology and Laboratory Medicine, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH, USA WEIJIE LI, MD, PHDDepartment of Pathology and Laboratory Medicine, Children's Mercy Hospital, University of Missouri-Kansas City School of Medicine, Kansas City, USA
About the Editor
Authors: Weijie Li, MD, PHD (Editor)
Journal: Leukemia (2022)

Weijie Li, MD, PhD, is an Associate Professor of Pathology and Laboratory Medicine at the University of Missouri-Kansas City School of Medicine and the Director of Hematopathology and Flow Cytometry at Children's Mercy Hospital, Kansas City, USA. He is a physician board-certified in anatomic pathology, clinical pathology, and hematopathology. He has clinical expertise in the diagnosis of leukemias/lymphomas and other hematolymphoid diseases, and laboratory monitoring of the therapeutic response of these diseases, especially in acute leukemias. He is actively involved in teaching and research. He is the principal investigator or co-investigator of multiple funded research projects. His research is focused on diagnostic and prognostic markers of leukemia/lymphoma, minimal residual disease detection of acute leukemia, flow cytometry study of hematolymphoid malignancy, and the deregulation of signaling pathway in pediatric leukemia/lymphoma. He has published extensively in these areas and served as a reviewer for multiple journals in these fields.
Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia
Authors: Ya-Fang Ma, Ying Lu, Qian Wu, Yin-Jun Lou, Min Yang, Jie-Yu Xu, Cai-Hong Sun, Li-Ping Mao, Gai-Xiang Xu, Li Li, Jian Huang, Huai-Yu Wang, Li-Jiang Lou, Hai-Tao Meng, Jie-Jing Qian, Wen-Juan Yu, Ju-Ying Wei, Zhen-Yu Li, Xue-Lu Zhu, Xiao-Yan Yan, Su-Ning Chen, Jie Jin, Hong-Hu Zhu
Journal: Journal of Hematology & Oncology (2022)

Abstract Acute promyelocytic leukemia (APL) has become curable over 95% patients under a complete chemo-free treatment with all-trans retinoic acid (ATRA) and arsenic trioxide in low-risk patients. Minimizing chemotherapy has proven feasible in high-risk patients. We evaluated oral arsenic and ATRA without chemotherapy as an outpatient consolidation therapy and no maintenance for high-risk APL. We conducted a multicenter, single-arm, phase 2 study with consolidation phases. The consolidation therapy included Realgar–Indigo naturalis formula (60 mg/kg daily in an oral divided dose) in a 4-week-on and 4-week-off regimen for 4 cycles and ATRA (25 mg/m 2 daily in an oral divided dose) in a 2-week-on and 2-week-off regimen for 7 cycles. The primary end point was the disease-free survival (DFS). Secondary end points included measurable resident disease, overall survival (OS), and safety. A total of 54 participants were enrolled at seven centers from May 2019. The median age was 40 years. At the median follow-up of 13.8 months (through April 2022), estimated 2-year DFS and OS were 94% and 100% in an intention-to-treat analysis. All the patients achieved complete molecular remission at the end of consolidation phase. Two patients relapsed after consolidation with a cumulative incidence of relapse of 6.2%. The majority of adverse events were grade 1–2, and only three grade 3 adverse events were observed. Oral arsenic plus ATRA without chemotherapy was active as a first-line consolidation therapy for high-risk APL. Trial registration : chictr.org.cn number, ChiCTR1900023309.
Preface
Journal: Leukemia (2022)

Leukemia is a heterogeneous group of hematological malignancies characterized by the proliferation of abnormal lymphoid or hematopoietic cells in the bone marrow, frequently involving peripheral blood, spleen, and lymph nodes. Leukemia is the 10th most common human malignancy, with over 60,000 new cases diagnosed in the United States every year and approximately 1.5% of people diagnosed at some point during their lifetime. Tremendous advances have been made in the biology and genetics of leukemia during the past several decades, which have translated into significantly improved clinical management and survival outcome. This 10-chapter book provides the most up-to-date information on important topics such as prognostic and predictive biomarkers, new World Health Organization (WHO) classification, pharmacogenomics, and measurable (minimal) residual disease (MRD). Also included in this book are in-depth reviews of several interesting leukemia entities, which update these entities from various aspects including etiology, pathogenesis, histopathology, diagnosis, treatments, and clinical outcomes. The WHO classification of tumors has provided a unified tumor classification system enabling people across the world to share their experience, knowledge, and research results. Ongoing research work conducted by many researchers and physicians has been leading to our continuously improved understanding of tumors and the continual production of new editions of WHO classification with updates. CONTINUE READING…..
Acute Myeloid Leukemia with Myelodysplasia Related Changes
Authors: Motoharu Shibusawa, Tetsuya Tanimoto
Journal: Leukemia (2022)

Acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) is one of the common subtypes of AML. It accounts for approximately 20% of newly diagnosed AML. The World Health Organization classification 2017 defines AML-MRC as acute leukemia with ≥20% blasts in the peripheral blood or bone marrow with morphological features of myelodysplasia, or occurring in patients with a prior history of myelodysplastic syndrome (MDS) or myelodysplastic/myeloproliferative neoplasm (MDS/MPN), with MDS related cytogenetic abnormalities, and the absence of specific genetic abnormalities of AML with recurrent genetic abnormalities. In diagnosing AML-MRC, there are three main criteria; the presence of (i) dysplasia; (ii) chromosomal abnormalities associated with AML-MRC; and (iii) a prior history of MDS or MDS/MPN. Therefore, AML-MRC is a heterogeneous disease, and the prognosis of each AML-MRC varies widely. AML-MRC is usually treated with chemotherapy, and hematopoietic stem cell transplantation is one of the treatment options. Prognostic factors should be considered in planning a treatment strategy for each case.
Publisher Correction: SAIGE-GENE+ improves the efficiency and accuracy of set-based rare variant association tests
Authors: Wei Zhou, Wenjian Bi, Zhangchen Zhao, Kushal K. Dey, Karthik A. Jagadeesh, Konrad J. Karczewski, Mark J. Daly, Benjamin M. Neale, Seunggeun Lee
Journal: Nature Genetics (2022)